Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial

IMPORTANCE: Mismatch repair deficiency (dMMR) occurs in various cancers, and these tumors are attractive candidates for anti–programmed cell death 1 therapies, such as dostarlimab, a recently approved immune checkpoint inhibitor. OBJECTIVE: To assess the antitumor activity and safety of dostarlimab...

Descripción completa

Detalles Bibliográficos
Autores principales: André, Thierry, Berton, Dominique, Curigliano, Giuseppe, Sabatier, Renaud, Tinker, Anna V., Oaknin, Ana, Ellard, Susan, de Braud, Filippo, Arkenau, Hendrik-Tobias, Trigo, José, Gravina, Adriano, Kristeleit, Rebecca, Moreno, Victor, Abdeddaim, Cyril, Vano, Yann-Alexandre, Samouëlian, Vanessa, Miller, Rowan, Boni, Valentina, Torres, Antonio Antón, Gilbert, Lucy, Brown, Jubilee, Dewal, Ninad, Dabrowski, Christine, Antony, Grace, Zografos, Eleftherios, Veneris, Jennifer, Banerjee, Susana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623195/
https://www.ncbi.nlm.nih.gov/pubmed/37917058
http://dx.doi.org/10.1001/jamanetworkopen.2023.41165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623195/
https://www.ncbi.nlm.nih.gov/pubmed/37917058
http://dx.doi.org/10.1001/jamanetworkopen.2023.41165

Ejemplares similares